uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
Uniqure Nv stock last closed at $14.39, up 8.28% from the previous day, and has increased 198.55% in one year. It has overperformed other stocks in the Biotechnology industry by 2.75 percentage points. Uniqure Nv stock is currently +285.79% from its 52-week low of $3.73, and -24.97% from its 52-week high of $19.18.
As of Apr 22, 2025, there are 54.08M shares of QURE outstanding. The market cap of QURE is $778.17M. In the past 24 hours, 1.71M QURE shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy QURE shares.
Based on our research, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen the right brokerage, you need to fill out some personal information so you are able to invest in QURE stock today.
Now that you have filled out your info on the best stock market app, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring money into your new investment account.
After you have decided on the best place to buy Uniqure Nv stock, it's critical to analyze their stock before you invest, so you can wrap your head around the risk as well as the upside.
WallStreetZen was created to help average investors perform more accurate fundamental analysis in less time.
You can see all of the due diligence checks on QURE's stock page.
You can use many financial metrics, analyses, models, and charts to gauge QURE's fair value.
You can access additional valuation analysis on QURE's stock here.
Out of 9 Equities analysts who give recommendations on QURE, the consensus analyst rating on QURE is a Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Paul Matteis, a bottom 5% analyst from Stifel Nicolaus maintains QURE with a strong buy rating and raises their QURE price target from $12.00 to $32.00, on Dec 16, 2024.
Salveen Richter, a bottom 14% analyst from Goldman Sachs maintains QURE with a hold rating and raises their QURE price target from $9.00 to $20.00, on Dec 12, 2024.
An analyst from Leerink Partners maintains QURE with a buy rating and raises their QURE price target from $26.00 to $44.00, on Dec 11, 2024.
Danielle Brill, a bottom 8% analyst from Raymond James upgrades QURE to a strong buy rating and raises their QURE price target from $20.00 to $52.00, on Dec 10, 2024.
Kristen Kluska, a top 2% analyst from Cantor Fitzgerald maintains QURE with a strong buy rating and raises their QURE price target from $28.00 to $58.00, on Dec 10, 2024.
Cantor Fitzgerald's Kristen Kluska raised their price target on Uniqure Nv (NASDAQ: QURE) by 107.1% from $28 to $58 on 2024/12/10. The analyst maintained their Strong Buy rating on the stock.
On 2024/12/10, Uniqure NV announced its alignment with the FDA on key elements of the accelerated approval pathway for AMT-130 in Huntington’s Disease, Kluska told investors.
In the agreement, the FDA acknowledged that the present study's data might be used to apply for an accelerated biologics license, the analyst explained.
With "a possible green light for the way forward," Kluska thinks Uniqure NV may see substantial interest from the pharmaceutical industry.
AMT-130 is an experimental gene therapy developed by Uniqure for the treatment of Huntington's disease.
Huntington's disease is a genetic disorder that causes the progressive breakdown of nerve cells in the brain, leading to severe physical and mental disabilities1.
You can dig deeper into what analysts are saying on the Uniqure Nv stock forecast page.
Last year, QURE revenue was $27.12M. Over the past five year, QURE's revenue has increased by 30.08% per year. This was slower than the Biotechnology industry average of 44.4%.
You can research QURE's earnings and revenue performance here.
Over the past year, executives and large shareholders at QURE have sold more shares than they have bought.
Walid Abisaab, Chief Medical Officer of QURE, was the latest QURE insider to sell. They sold $13,891.50 worth of QURE stock on Mar 4, 2025.
Research more about who owns QURE shares here.
No, Uniqure Nv doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two main options:
Press the Open Trade button and your broker will place the order.
If you need more assistance investing in stocks on eToro, click the helpful video below:
Now that you own some QURE stock, you'll want to keep up with your stock purchase.
Create a watchlist to get notified of important updates regarding your QURE stock.
To reiterate, here are the 6 steps to buy Uniqure Nv stock:
If you require a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Uniqure Nv, create a watchlist today.